Position in LYEL
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$2,979,230
+$722,595 QoQ
Shares Held
148,516
+102.6% QoQ
Ownership
0.636%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
3 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in LYEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026MARSHALL WACE, LLP holds $2,766,756,129 across 280 Biotechnology names. LYEL ranks #133 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
1,099,318 | $363,731,344 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
317,058 | $141,579,078 | |
| 3 | INCY |
Incyte Corp
|
1,253,138 | $117,945,347 | |
| 4 | RPRX |
Royalty Pharma plc
|
2,120,692 | $101,729,594 | |
| 5 | RCUS |
Arcus Biosciences, Inc.
|
3,761,437 | $81,247,039 | |
| 6 | PTGX |
Protagonist Therapeutics, Inc
|
628,075 | $66,199,104 | |
| 7 | ROIV |
Roivant Sciences Ltd.
|
2,246,943 | $62,240,320 | |
| 8 | COGT |
Cogent Biosciences, Inc.
|
1,600,168 | $61,590,466 |
All Filings in LYEL
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,979,230 | 148,516 | Shares | Other | 2026-05-15 | |
| 2025-12-31 | $2,256,635 | 73,315 | Shares | Other | 2026-02-13 | |
| 2025-06-30 | $93,527 | 10,580 | Shares | Other | 2025-08-13 | |
| No filing history on record for this holder in this stock. | ||||||